“Advancement of Image-Guided and Drug-Eluting Technologies”
- A significant and accelerating trend in the global Transarterial Chemoembolization (TACE) market is the growing adoption of advanced imaging techniques and the development of drug-eluting bead (DEB) technologies, which enhance the precision, safety, and efficacy of localized chemotherapy for liver cancer patients
- For instance, Siemens Healthineers and Philips have introduced AI-enhanced interventional radiology platforms that allow real-time tumor targeting and optimized embolization outcomes. Similarly, Biocompatibles UK Ltd. (a BTG International group company) has seen increased use of its LC Bead® in DEB-TACE procedures, which offers sustained drug release and reduced systemic toxicity
- Innovations in drug-eluting bead formulations, such as CalliSpheres® and DC Bead LUMI™, enable improved visualization and targeted delivery, resulting in better tumor response and reduced side effects. In addition, AI-assisted imaging systems are improving pre-procedural planning, enabling oncologists to tailor embolization based on individual patient anatomy and tumor vascularity
- The integration of these technologies facilitates more effective and personalized treatment, driving clinician confidence and expanding the use of TACE beyond hepatocellular carcinoma to secondary liver tumors
- This trend toward precision oncology and minimally invasive intervention is redefining interventional cancer treatment protocols. As a result, leading players such as Guerbet and Terumo Corporation are investing in image-guided drug delivery innovations and expanding their embolization product portfolios to capture emerging demand in both developed and developing markets
- The demand for technologically advanced and targeted TACE procedures is rising sharply across oncology centers worldwide, as healthcare providers increasingly aim for improved patient outcomes, shorter recovery times, and reduced hospital stays
